News

Report: ‘Salonistas’ contribute to robust growth in DIY nail care market

BY Antoinette Alexander

ROCKVILLE, Md. — Several intertwined factors are fueling the mass nail care market, and according to a new report by Packaged Facts, the growth of do-it-yourself nail products is expected to continue despite an uptick in professional nail services.

SymphonyIRI Group, a Chicago-based market research firm, reported that sales of nail care products grew 26% for the 52 weeks ended April 15 at food, drug and mass (excluding Walmart). Nail polish sales, in particular, grew about 43% during that time.

Several intertwined factors are driving the market, Packaged Facts stated. A nailcentric fashion culture has transformed women’s nails into stylish accessories, even as a continuing flood of innovative, fashion-forward nail care products empower women to affordably imitate nail salon effects in their own homes. Therefore, a growing population of women make frequent use of DIY nail care products.

According to the Nails Magazine 2011-2012 "Big Book," the nail salon services market fell nearly 5% in 2009 and was still below its 2008 level in 2010. However, all signs now point to a return to popularity of nail salon services. According to Experian Simmons data cited in the Packaged Facts report, an improving economic picture has resulted in a sharp uptick in the number of women obtaining frequent professional nail care services. In 2011, the number of women having two or more manicures in a six-month period (defined as "salonistas" by Packaged Facts) increased from 16.3 million to 18.1 million, or 11.3%.

The question now facing nail care product marketers is whether DIY nail care sales will decline as women return to salons to get professional manicures and pedicures. According to David Sprinkle, the publisher of Packaged Facts, "the data strongly suggest that the reverse will be true." The more women go to salons for manicures, the more they buy and use DIY nail care products.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA accepts NDA for Agile’s contraceptive patch

BY Allison Cerra

PRINCETON, N.J. — The Food and Drug Administration has accepted a new drug application for a low-dose, once-weekly contraceptive patch from Agile Therapeutics, the drug maker said.

Agile said it expects the FDA to respond to its NDA for AG200-15 — a combination hormonal contraceptive patch, which in clinical studies has been shown to deliver a low dose of ethinyl estradiol, as well as a dose of levonorgestrel that is consistent with that of low-dose oral contraceptives — by first quarter 2013. The patch is applied once weekly for three weeks, followed by a fourth patch-free week. The patch may be applied to the abdomen, buttocks or upper torso, is soft and flexible with a cloth-like, silky feel and designed to provide adhesion, comfort and appearance, Agile said.

"We are very pleased with the FDA’s acceptance of our AG200-15 NDA filing," Agile president and CEO Al Altomari said. "This is an important milestone for our company and reflects the unwavering commitment of the entire Agile team to advance a new contraceptive option for women. We will work closely with the FDA to bring AG200-15 to market as soon as possible."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Amgen completes Kai acquisition

BY Allison Cerra

THOUSAND OAKS, Calif. — Amgen has completed its acquisition of Kai Pharmaceuticals, a privately held company based in South San Francisco, Calif.

The deal, first announced in April, is valued at $315 million. The deal also includes the acquisition of KAI-4169, an experimental drug Kai is developing for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI previously reported compelling mid-stage clinical results for KAI-4169 in this indication.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?